3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Thromboembolism
1
Pulmonary Embolism
1
Pancreatic Neoplasms
1
Interventions
pembrolizumab
222
Carboplatin
215
Cisplatin
203
Paclitaxel
181
Gemcitabine
148
Docetaxel
126
Capecitabine
114
Cyclophosphamide
102
Pemetrexed
100
Dexamethasone
100
Specimen Handling
99
Magnetic Resonance Spectroscopy
97
Oxaliplatin
96
Radiotherapy
94
Doxorubicin
91
Fluorouracil
88
Bevacizumab
84
Leucovorin
73
Nivolumab
72
Rituximab
71
Vincristine
68
durvalumab
65
Lenalidomide
64
Radiation
62
atezolizumab
61
Irinotecan
61
Etoposide
60
130-nm albumin-bound paclitaxel
58
Prednisone
55
Letrozole
55
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
isoquercitrin
×
1 year
×
Clear all
NCT06861088
2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3
Recruiting
480 enrolled